Turning on the radio

Epigenetic inhibitors as potential radiopriming agents

Bryan Oronsky, Jan Scicinski, Michelle M. Kim, Pedro Cabrales, Michael E. Salacz, Corey A. Carter, Neil Oronsky, Harry Lybeck, Michelle Lybeck, Christopher Larson, Tony R. Reid, Arnold Oronsky

Research output: Contribution to journalReview article

Abstract

First introduced during the late 1800s, radiation therapy is fundamental to the treatment of cancer. In developed countries, approximately 60% of all patients receive radiation therapy (also known as the sixty percenters), which makes radioresistance in cancer an important and, to date, unsolved, clinical problem. Unfortunately, the therapeutic refractoriness of solid tumors is the rule not the exception, and the ubiquity of resistance also extends to standard chemotherapy, molecularly targeted therapy and immunotherapy. Based on extrapolation from recent clinical inroads with epigenetic agents to prime refractory tumors for maximum sensitivity to concurrent or subsequent therapies, the radioresistant phenotype is potentially reversible, since aberrant epigenetic mechanisms are critical contributors to the evolution of resistant subpopulations of malignant cells. Within the framework of a syllogism, this review explores the emerging link between epigenetics and the development of radioresistance and makes the case that a strategy of pre- or co-treatment with epigenetic agents has the potential to, not only derepress inappropriately silenced genes, but also increase reactive oxygen species production, resulting in the restoration of radiosensitivity.

Original languageEnglish (US)
Article number32
JournalBiomolecules
Volume6
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Radiotherapy
Radio
Epigenomics
Tumors
Chemotherapy
Extrapolation
Refractory materials
Restoration
Reactive Oxygen Species
Genes
Cells
Neoplasms
Therapeutics
Radiation Tolerance
Developed Countries
Immunotherapy
Phenotype
Drug Therapy

Keywords

  • DNA methyltransferase inhibition
  • Epigenetic priming
  • Epigenetics
  • Histone deacetylase inhibition
  • Radiosensitization
  • Radiotherapy
  • Reactive oxygen species (ROS)

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry
  • Molecular Biology

Cite this

Oronsky, B., Scicinski, J., Kim, M. M., Cabrales, P., Salacz, M. E., Carter, C. A., ... Oronsky, A. (2016). Turning on the radio: Epigenetic inhibitors as potential radiopriming agents. Biomolecules, 6(3), [32]. https://doi.org/10.3390/biom6030032

Turning on the radio : Epigenetic inhibitors as potential radiopriming agents. / Oronsky, Bryan; Scicinski, Jan; Kim, Michelle M.; Cabrales, Pedro; Salacz, Michael E.; Carter, Corey A.; Oronsky, Neil; Lybeck, Harry; Lybeck, Michelle; Larson, Christopher; Reid, Tony R.; Oronsky, Arnold.

In: Biomolecules, Vol. 6, No. 3, 32, 01.09.2016.

Research output: Contribution to journalReview article

Oronsky, B, Scicinski, J, Kim, MM, Cabrales, P, Salacz, ME, Carter, CA, Oronsky, N, Lybeck, H, Lybeck, M, Larson, C, Reid, TR & Oronsky, A 2016, 'Turning on the radio: Epigenetic inhibitors as potential radiopriming agents', Biomolecules, vol. 6, no. 3, 32. https://doi.org/10.3390/biom6030032
Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA et al. Turning on the radio: Epigenetic inhibitors as potential radiopriming agents. Biomolecules. 2016 Sep 1;6(3). 32. https://doi.org/10.3390/biom6030032
Oronsky, Bryan ; Scicinski, Jan ; Kim, Michelle M. ; Cabrales, Pedro ; Salacz, Michael E. ; Carter, Corey A. ; Oronsky, Neil ; Lybeck, Harry ; Lybeck, Michelle ; Larson, Christopher ; Reid, Tony R. ; Oronsky, Arnold. / Turning on the radio : Epigenetic inhibitors as potential radiopriming agents. In: Biomolecules. 2016 ; Vol. 6, No. 3.
@article{702fc3e0ed2c40d68d1550e46527e863,
title = "Turning on the radio: Epigenetic inhibitors as potential radiopriming agents",
abstract = "First introduced during the late 1800s, radiation therapy is fundamental to the treatment of cancer. In developed countries, approximately 60{\%} of all patients receive radiation therapy (also known as the sixty percenters), which makes radioresistance in cancer an important and, to date, unsolved, clinical problem. Unfortunately, the therapeutic refractoriness of solid tumors is the rule not the exception, and the ubiquity of resistance also extends to standard chemotherapy, molecularly targeted therapy and immunotherapy. Based on extrapolation from recent clinical inroads with epigenetic agents to prime refractory tumors for maximum sensitivity to concurrent or subsequent therapies, the radioresistant phenotype is potentially reversible, since aberrant epigenetic mechanisms are critical contributors to the evolution of resistant subpopulations of malignant cells. Within the framework of a syllogism, this review explores the emerging link between epigenetics and the development of radioresistance and makes the case that a strategy of pre- or co-treatment with epigenetic agents has the potential to, not only derepress inappropriately silenced genes, but also increase reactive oxygen species production, resulting in the restoration of radiosensitivity.",
keywords = "DNA methyltransferase inhibition, Epigenetic priming, Epigenetics, Histone deacetylase inhibition, Radiosensitization, Radiotherapy, Reactive oxygen species (ROS)",
author = "Bryan Oronsky and Jan Scicinski and Kim, {Michelle M.} and Pedro Cabrales and Salacz, {Michael E.} and Carter, {Corey A.} and Neil Oronsky and Harry Lybeck and Michelle Lybeck and Christopher Larson and Reid, {Tony R.} and Arnold Oronsky",
year = "2016",
month = "9",
day = "1",
doi = "10.3390/biom6030032",
language = "English (US)",
volume = "6",
journal = "Biomolecules",
issn = "2218-273X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Turning on the radio

T2 - Epigenetic inhibitors as potential radiopriming agents

AU - Oronsky, Bryan

AU - Scicinski, Jan

AU - Kim, Michelle M.

AU - Cabrales, Pedro

AU - Salacz, Michael E.

AU - Carter, Corey A.

AU - Oronsky, Neil

AU - Lybeck, Harry

AU - Lybeck, Michelle

AU - Larson, Christopher

AU - Reid, Tony R.

AU - Oronsky, Arnold

PY - 2016/9/1

Y1 - 2016/9/1

N2 - First introduced during the late 1800s, radiation therapy is fundamental to the treatment of cancer. In developed countries, approximately 60% of all patients receive radiation therapy (also known as the sixty percenters), which makes radioresistance in cancer an important and, to date, unsolved, clinical problem. Unfortunately, the therapeutic refractoriness of solid tumors is the rule not the exception, and the ubiquity of resistance also extends to standard chemotherapy, molecularly targeted therapy and immunotherapy. Based on extrapolation from recent clinical inroads with epigenetic agents to prime refractory tumors for maximum sensitivity to concurrent or subsequent therapies, the radioresistant phenotype is potentially reversible, since aberrant epigenetic mechanisms are critical contributors to the evolution of resistant subpopulations of malignant cells. Within the framework of a syllogism, this review explores the emerging link between epigenetics and the development of radioresistance and makes the case that a strategy of pre- or co-treatment with epigenetic agents has the potential to, not only derepress inappropriately silenced genes, but also increase reactive oxygen species production, resulting in the restoration of radiosensitivity.

AB - First introduced during the late 1800s, radiation therapy is fundamental to the treatment of cancer. In developed countries, approximately 60% of all patients receive radiation therapy (also known as the sixty percenters), which makes radioresistance in cancer an important and, to date, unsolved, clinical problem. Unfortunately, the therapeutic refractoriness of solid tumors is the rule not the exception, and the ubiquity of resistance also extends to standard chemotherapy, molecularly targeted therapy and immunotherapy. Based on extrapolation from recent clinical inroads with epigenetic agents to prime refractory tumors for maximum sensitivity to concurrent or subsequent therapies, the radioresistant phenotype is potentially reversible, since aberrant epigenetic mechanisms are critical contributors to the evolution of resistant subpopulations of malignant cells. Within the framework of a syllogism, this review explores the emerging link between epigenetics and the development of radioresistance and makes the case that a strategy of pre- or co-treatment with epigenetic agents has the potential to, not only derepress inappropriately silenced genes, but also increase reactive oxygen species production, resulting in the restoration of radiosensitivity.

KW - DNA methyltransferase inhibition

KW - Epigenetic priming

KW - Epigenetics

KW - Histone deacetylase inhibition

KW - Radiosensitization

KW - Radiotherapy

KW - Reactive oxygen species (ROS)

UR - http://www.scopus.com/inward/record.url?scp=85012108992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012108992&partnerID=8YFLogxK

U2 - 10.3390/biom6030032

DO - 10.3390/biom6030032

M3 - Review article

VL - 6

JO - Biomolecules

JF - Biomolecules

SN - 2218-273X

IS - 3

M1 - 32

ER -